April 2018

New Product - Darzalex

Darzalex (daratumumab (rch)) is an IgG1κ human monoclonal antibody that binds to the CD38 protein expressed at a high level on the surface of cells in a variety of haematological malignancies, including multiple myeloma tumour cells. Darzalex is indicated: in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are refractory to both a PI and an immunomodulatory agent. Darzalex is available in single vials containing 100 mg and 400 mg.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au